Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

Surgical Treatment for T4 Non-small Cell Lung Cancer Invading Mediastinal Structures

종격동 구조물을 침범한 T4 비소세포폐암의 수술적 치료

  • 황은구 (건국대학교 의과대학 흉부외과학교실) ;
  • 이해원 (원자력병원 흉부외과) ;
  • 정진행 (원자력병원 병리과) ;
  • 박종호 (원자력병원 흉부외과) ;
  • 조재일 (국립암센터 폐암센터) ;
  • 심영목 (성균관대학교 의과대학 삼성서울병원 흉부외과) ;
  • 백희종 (원자력병원 흉부외과)
  • Published : 2004.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Non-small cell lung cancer (NSCLC) with invasion of mediastinal structures is classified as stage IIIB, and has been considered surgically unresectable However, in a selected group of these patients, better results after surgical resection compared to non-surgical group have been reported. The aim of this study is to evaluate the role of surgical resection in treatment of mediastinal T4 NSCLC. Material and Method: Among 1067 patients who underwent surgical intervention for non-small cell lung cancer from Aug 1987 to Dec 2001 in Korea cancer center hospital, 82 patients had an invasion of T4 mediastinal structures (7.7%). Resection was possible in 63patients (63/82 resectability 76.8%). Their medical records in Data Base were reviewed, and they were followed up completely until Jun 2002. Surgical results and prognostic factors of NSCLC invading mediastinal structures were evaluated retrospectively. Result Lung cancer was resected completely in 52 patients (63.4%, 52/82). Lung resection was lobectomy (or more) in 14, pneumonectomy in 49. The mediastinal structures invaded by primary tumor were great vessel (61.9%), heart (19%), vagus nerve (9.5%), esophagus (7.9%), and vertebral body (7.9%). Nodal status was N0 in 11, N1 in 24, and N2 in 28 (44.4%). Neoadjuvant therapy was done in 6 (9.5%, 5 chemotherapy, 1 radiotherapy), and adjuvant therapy was added in 44 (69.8%, 15 chemotherapy, 29 radiotherapy) in resection group (n=63). Complication was occurred in 23 (31.7%), and operative mortality was 9.5% in resection group. Median and 5 year overall survival including operative mortality was 18.1 months and 21.7% in resection group (n=63), 6.2months and 0% in exploration only group (n=19, p=.001), 39 months and 32.9% in N2 (-) resection group (n=35), and 8.8 months and 8.6% in N2 (+) resection group (n=28, p=.007). The difference of overall survival by mediastinal structure was not significant. Conclusion: The operative risk of NSCLC invading mediastinal structures was high but acceptable, and long-term result of resection was favorable in selected group. Aggressive resection is recommended in well selected pateints with good performace and especially N2 (-) NSCLC with mediastinal invasion.

비소세포폐암에서 종격동 구조물을 침습한 경우 일반적으로 외과적인 절제가 불가능한 것으로 알려져 있으며 Stage IIIB로 분류된다. 그러나 잘 선택된 일부 환자 군에서 절제수술 후 비수술군보다 좋은 결과가 보고된 바 있다. 본 연구의 목적은 종격동 구조물을 침범한 T4 비소세포 폐암의 치료에서 수술의 역할에 대해 알아보고자 한다. 대상 및 방법: 1987년 8월부터 2001년 12월까지 원자력병원 흉부외과에서 비소세포폐암으로 수술한 총 1067예 중 T4 종격동 구조물을 침습한 비소세포폐암은 82 예(7.7%)였고, 이 중 절제가 가능한 예는 63예(63/82 절제율 76.8%)였다. 63예의 의무기록과 데이터베이스를 분석하고 모든 환자에 대하여 2002년 6월까지 추적조사를 마쳤다. 종격동 구조물을 침범한 비소세포폐암의 수술 결과와 예후 인자를 후향적으로 분석하였다. 결과: 82예 중 완전절제가 가능한 경우가 52예(63.4% 52/82)였다. 폐절제는 단일 폐엽 또는 단일 궤엽 이상 절제술 14예(22.2%), 전폐절제술 49예(77.8%)였다. 원발 종양에 의해 침범된 구조물(중복)은 대혈관이 39예(61.9%)로 가장 많았으며, 그밖에 심장 12예(19%), 미주신경 6예(9.5%), 식도 5예(7.9%), 척추 5예(7.9%), 기관 분기부 5예(7.9%) 등이었다. 림프절 전이는 pN0 11예, pNl 24예, pN2 28예(44.4%)였다. 술 전 보조치료는 모두 6예(9.5%, 5 항암화학요법, 1 방사선요법)에서 시행하였으며 절제수술 63예 중 44예에서 술 후 보조치료(69.8%, 15 항암화학요법, 29 방사선요법)가 시행되었다. 술 후 합병증으로는 23예(36.5%), 수술 사망률은 9.5% (6/63)였다. 절제 수슬(n=63) 후 중앙 생존값과 5년 생존율은 각각 18.1개월과 21.7%였고, 절제 불가능 군(O＆C)(n=19)은 중앙 생존값 6.2개월, 5년 생존율 0%였다(p=.001). N2 림프절 전이가 없었던 군(N0-1, n=35)의 중앙 생존값 39개월, 5년 생존율 32.9%로 N2 림프절 전이가 있었던 군(n=28)의 중앙 생존값 8.8개월, 5년 생존율 8.6%보다 높았다(p=.007). 침습한 구조물의 종류에 따른 생존율의 차이는 없었다(p=.2). 결론: 종격동 구조물을 침범한 T4 비소세포폐암에서의 수술 위험도는 높은 편이나 용납될 수준이며 환자의 전신상태 등 술 전 세심한 환자선택 특히 종격동 림프절의 전이가 없을 경우 적극적인 절제 수술이 권장된다.

Keywords

References

  1. AJCC Cancer Staging Manual(5th ed.) American Joint Committee on Cancer
  2. Surg Clin N Am v.82 Radical resections for T4 lung cancer Rice,T.W.;Balckstone,E.H. https://doi.org/10.1016/S0039-6109(02)00017-8
  3. Lung Cancer v.21 Prognostic implications of pulmonary satellite nodules: Are the 1997 staging revisions appropriate? Urschel,J.D.;Urschel,D.M.;Anderson,T.M.;Antkowiak,J.G.;Takia,H. https://doi.org/10.1016/S0169-5002(98)00038-5
  4. J Thorac Cardiovasc Surg v.96 Prognosis and survival in resected lung carcinoma based on the new international staging system Naruke,T.;Goya,T.;Tsuchiya,R.;Suemasu,R.
  5. Ann Thorac Surg v.58 Management of non-small cell lung cancer with direct mediastinal involvement Martini,N.;Yellin,A.;Ginsberg,R.J.(et al.) https://doi.org/10.1016/0003-4975(94)91933-X
  6. J Thorac Cardiovasc Surg v.117 Induction chemotherapy for T4 centrally located non-small cell lung cancer Rendina,E.A.;Venuta,F.;De Giacoma,T.(et al.) https://doi.org/10.1016/S0022-5223(99)70416-2
  7. Ann Thorac Surg v.69 Extended resection for bronchogenic carcinoma invadong the superior vena cava system Spaggiari,L.;Regnard,J.F.;Magdeleinat,P.;Jauffret,B.;Puyo,P.;Levasseur,P. https://doi.org/10.1016/S0003-4975(99)00867-X
  8. J Thorac Cardiovasc Surg v.110 Risk analysis and long-term survival in patients undergoing extended rtesection of locally advanced lung cancer Izbicki,J.R.;Knoefel,W.T.;Passlick,B.;Habekost,M.;karg,O.;Thetter,O. https://doi.org/10.1016/S0022-5223(95)70235-0
  9. Eur J Cardiothorac Surg v.20 Risk analysis and long-term survival in patients in patients indergoing resection of T4 lung cancer Bernard,A.;Bouchot,O.;Hagry,O.;Favre,J.P. https://doi.org/10.1016/S1010-7940(01)00788-6
  10. Eur J Cardiothorac Surg v.20 Is lung cancer surgery justified in patients with direct mediastinal invasion? Doddoli,C.;Rollet,G.;Thomas,P.(et al.) https://doi.org/10.1016/S1010-7940(01)00759-X
  11. Ann Thorac Surg v.64 Thoracoscopic staging of IIIB non-small cell lung cancer before neoadjuvant therapy De Giacomo,T.;Rendina,E.A.;Venuta,F.;Della Rocca,G.;Ricci,C. https://doi.org/10.1016/S0003-4975(97)00764-9
  12. 2003년 대한폐암연구회 추계학술대회지 Improved results of mediastinal nodal staging in NSCLC by FDG-PET H.J.Baek;J.M.Shin;H.W.Lee(et al.)
  13. Eur J Cardiothorac Surg v.11 Extended operation for non-small cell lung cancerinvading great vessles and left atrium Fukuse,T.;Wada,H.;Hitomi,S. https://doi.org/10.1016/S1010-7940(96)01140-2
  14. Lancet v.352 Postoperative radiotherapy in non-small cell lung cancer: systemic review ans meta-analysis of individual patient data from nine randomised controlled trials Port Meta-Analysis Trialist Group https://doi.org/10.1016/S0140-6736(98)06341-7
  15. Chest v.106 Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881 Wagner,Jr.H.;Lad,T.;Piantadosi,S.;rickdeschel,J.C. https://doi.org/10.1378/chest.106.6.348S
  16. Ann Thorac Surg v.57 Extended operations after induction therapy for stage IIIb(T4) non-small cell lung cancer Maccia rini,P.;Chapelier,A.R.;Monnet,I.(et al.) https://doi.org/10.1016/0003-4975(94)90215-1
  17. Lung Cancer v.22 Induction chemotherapy for advanced stage III non-small cell lung cancer long-term follow-up in 42 patients Katakami,N.;Okazaki,M.;Nishiuchi,S.(et al.) https://doi.org/10.1016/S0169-5002(98)00073-7
  18. J Clin Oncol v.15 Clinical practice guidelines of the treatment of unresectable non-small cell lung cancer American Society of Clinical Oncology